1 ML ERYTHROPOIETIN-epbx 10000 UNT/ML Injection [Retacrit]
- RxCUI
- 2047596
- RxNorm name
- 1 ML ERYTHROPOIETIN-epbx 10000 UNT/ML Injection [Retacrit]
- Display name
- 1 ML ERYTHROPOIETIN-epbx 10000 UNT/ML Injection [Retacrit]
- Full name
- 1 ML ERYTHROPOIETIN-epbx 10000 UNT/ML Injection [Retacrit]
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:38:54
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125545 | Retacrit | epoetin alfa-epbx | 351(k) Biosimilar | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| RETACRIT | EPOETIN ALFA-EPBX | Vifor (International) Inc. | e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | 2025-06-22 | Boxed warning, Warnings, Adverse reactions | 2047596 |
| RETACRIT | EPOETIN ALFA-EPBX | Pfizer Laboratories Div Pfizer Inc | 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | 2025-06-22 | Boxed warning, Warnings, Adverse reactions | 2047596 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | 1 ML ERYTHROPOIETIN-epbx 10000 UNT/ML Injection [Retacrit] | SY | 19 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | Retacrit 10,000 UNT per 1 ML Injection | SY | 19 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | 1 ML Retacrit 10000 UNT/ML Injection | SY | 19 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | Retacrit 10,000 UNT in 1 ML Injection | PSN | 19 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | 1 ML epoetin alfa-epbx 10000 UNT/ML Injection [Retacrit] | SBD | 19 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | 1 ML EPO-epbx 10000 UNT/ML Injection [Retacrit] | SY | 19 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | 1 ML ERYTHROPOIETIN-epbx 10000 UNT/ML Injection [Retacrit] | SY | 14 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | 1 ML Retacrit 10000 UNT/ML Injection | SY | 14 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | Retacrit 10,000 UNT in 1 ML Injection | PSN | 14 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | 1 ML epoetin alfa-epbx 10000 UNT/ML Injection [Retacrit] | SBD | 14 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | 1 ML EPO-epbx 10000 UNT/ML Injection [Retacrit] | SY | 14 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |
| e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | Retacrit 10,000 UNT per 1 ML Injection | SY | 14 | These highlights do not include all the information needed to use RETACRIT safely and effectively. See full prescribing information for RETACRIT. RETACRIT ® (epoetin alfa-epbx) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2018 RETACRIT (epoetin alfa-epbx) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically mean | 20250622 |